Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
Tweet Send to a Friend
BMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE